NETWORK-1 TECHNOLOGIES, INC. (NTIP) stock intrinsic value fair value estimate & owner earnings analysis

Network-1 Technologies licenses a portfolio of patents and collects revenue mainly through litigation and settlements rather than ongoing product sales. Its two full-time employees and two consultants manage a shrinking set of patent families: the company's historically largest earner, a patent covering power delivery over network cables, expired in 2020 and is no longer pursued; two other older portfolios have also fully expired, including one behind a lawsuit against Google and YouTube that a court dismissed and that is now on appeal, with a decision pending as of early 2026. What remains active are three portfolios covering machine-to-machine/IoT technology, high-frequency trading technology, and a newer, still-developing smart-home portfolio. Because Network-1's income is driven by occasional lawsuits and settlements rather than steady sales, its results swing enormously from year to year — two blowout years in the past decade delivered far more per share than all the other years combined, while most years were flat to modestly money-losing as legal and administrative costs ran ahead of licensing income. Our estimate of the company's normal, ongoing earning power is essentially breakeven, reflecting what a "typical" year looks like between settlements rather than what a settlement year looks like. We valued the company on this basis for 10 years and then assumed nothing beyond that: with the company's core patents already substantially expired and no visible pipeline of new intellectual property to replace them, we don't think it's reasonable to assume the licensing business continues indefinitely. That single judgment — treating the patent portfolio as a wasting asset with no residual value after year 10, rather than assuming it goes on forever — is the most important call in this analysis, and it is the main reason the estimated value is modest to negative. Our bear case assumes the pending appeal fails, the remaining active portfolios generate no further settlements, and the company continues to run at a modest loss for years, which we estimate is worth roughly negative $0.66 per share on a pure earnings basis. Our base case assumes results stay close to the recent trend before gradually settling into the historical "quiet year" pattern, worth roughly negative $0.19 per share. Our bull case assumes the pending appeal succeeds and leads to a further recovery on the Cox portfolio, and that the remaining active portfolios (M2M/IoT and high-frequency trading) produce a settlement broadly comparable to the company's past wins; that scenario is worth roughly $0.78 per share. Because our base case is at or below zero, the margin-of-safety price is not set above $0 under this method — the recurring economics of the licensing business, on their own, don't currently support a positive standalone value, even though upside exists if the pending litigation breaks the company's way. Two things are worth flagging that sit outside this earnings-based valuation entirely. First, Network-1 holds a meaningful amount of cash and short-term investments, and pays a small semi-annual dividend, which this method doesn't add to the figures above. Second, the company holds roughly a 5% stake in a private biotech company developing a whooping-cough vaccine, acquired for $7 million; that company just closed a large new financing round (announced February 2026) led by an outside institutional investor, which could indicate the stake is worth more than its carrying value — but because it's a private, non-cash holding, we have not attempted to price it here and it does not appear in the figures above. A reader weighing these shares should be aware both exist alongside the licensing business we valued.